Arijit Bhowmick, Ph.D. Email and Phone Number
Arijit Bhowmick, Ph.D. work email
- Valid
Arijit Bhowmick, Ph.D. personal email
- Valid
Currently leading Insitro's oligo therapy drug discovery efforts across targets, modalities, and therapeutic areas- from early stage design/screening to DC nomination and development (design and screening, oligonucleotide chemistry and delivery, pk/pd and met ID, off-target profiling, IVIVC, rodent and NHP DC enabling studies) Previous : Oligonucleotide therapeutics drug discovery and development executive with more than 11 years of experience in the field of oligonucleotide and RNA therapy. Built and led drug discovery teams from the ground up and established early-stage screening and discovery pipelines both in start-up and big biotech settings. Ex- Regeneron- Established Regeneron’s Nucleic Acid Therapeutics group under Regeneron Genetics Medicine (RGM) and led three teams (total of 14 FTE reports) that focused on oligonucleotide-based drug discovery and technology development (siRNA, ASO, Blocking oligo, mRNA, aptamer). Supported Regeneron-Alnylam collaboration as an SME from Regeneron side. External consultant - Serves as a technology consultant for investor due diligence in the oligonucleotide/nucleic acid therapy space ( Curie.bio, Guidepoint global)Core competencies : #RNAi | #ASO | #Aptamer | #Geneticmedicine | #Drug discoveryOligonucleotide drug discovery and pre-clinical development; siRNA/ASO design, screening and lead optimization; oligonucleotide chemical modification; aptamer selection and SELEX; mRNA design; Oligonucleotide pre-clinical PK/PD study design; building and managing multi-disciplinary drug discovery teams; due diligence for in-licensing/partnerships/external innovation; managing CRO partnerships
-
Director, Heading Oligonucleotide Therapeutics Drug DiscoveryInsitro Dec 2023 - PresentSouth San Francisco, California, UsDrug discovery and development from early stage screening to DC nomination
-
Scientific Advisor/External ConsultantCurie.Bio, Guidepoint Global Aug 2020 - PresentScientific advisor in oligonucleotide therapeutics space helping clients take strategic/investment decisions
-
Group Leader, Head Of Nucleic Acid Therapeutics Group, Regeneron Genetics Medicine (Rgm)Regeneron Aug 2022 - Nov 2023Tarrytown, New York, UsHeaded the NAT group at Regeneron (comprising 14 FTE reports, 3 teams) working on several internal and collaboration projects related to siRNA/ASO/mRNA/CRISPR, across several disease areas and targets. -
Group Leader, Head Of Nucleic Acid Therapy, Velocimmune NextRegeneron Dec 2021 - Aug 2022Tarrytown, New York, Us- Built a therapeutic mRNA discovery and development team ground-up, to add to Regeneron's expanding efforts in the area of nucleic acid therapeutics - Established mRNA design and generation (small and mid scale) pipeline for therapeutics/tool development- Led 3 teams focused on RNA/Oligonucleotide based therapeutics and expanded technology/platform development efforts by initiating collaborations with multiple groups within the company
-
Staff Scientist, Heading Oligo Therapy Team And Crispr Ex-Vivo Editing Team, Velocimmune NextRegeneron Jan 2021 - Dec 2021Tarrytown, New York, Us- Built the ex-vivo gene editing team under VI-Next umbrella to add to Regeneron's expanding genetic medicine efforts. Established gRNA design and screening (on/off target effect analysis) pipeline to support in-vivo/ex-vivo gene editing efforts- Expanded both the oligo therapy and editing teams to support oligo therapy and gene editing needs across multiple indications and disease areas- Worked with BD to evaluate external assets in the RNA therapy space for partnerships and/or acquisitions
-
Lead Scientist, Heading Oligonucleotide Therapy R&D Core Team (Vi Next)Regeneron Mar 2019 - Dec 2020Tarrytown, New York, Us- Built the oligo therapy core team at Regeneron under the VI-Next umbrella (lab set up, FTE hiring, strategy/planning), with primary focus on R&D efforts related to nucleic acid based drug discovery and technology development (RNAi, ASO, Aptamers)- Established Regeneron's oligonucleotide designing (siRNA, ASO, SSO), screening and discovery pipeline- Initiated technology/platform development efforts related to nucleic acid therapeutics targeted delivery and chemistry- Worked with internal collaborators and external partners to drive RNA based drug discovery and development at Regeneron- Worked with Regeneron's scientific leadership team and BD to develop strategies for expansion of efforts in genetic medicine space
-
Discovery Lead Scientist (Oligonucleotide Therapeutics/Rna)Vitrisa Therapeutics Jul 2017 - Mar 2019Larkspur, California, Us• Led a team of biologists and chemists to establish Vitrisa’s drug discovery pipeline• Created lead molecule profile (LMP) for drug candidates based on target occupancy and half-life modeling, indication, MOA prediction, and analysis of competitive molecules/assets, safety profile• Designed strategies for screening and discovery of RNA ligands, from early-stage discovery to IND candidate nomination• Used chemical modifications and devised SAR strategies to improve potency and stability of RNA aptamers for ophthalmology indications• Worked with CROs to plan in-vivo tox, pk/pd studies to support IND enabling efforts • Designed IP strategies and wrote white papers, tech summaries and patent applications surrounding new drug candidates, platform technologies, and processes• Worked with the C-suite to develop pitch and due-diligence decks for financing and BD partnerships• Managed drug discovery efforts across multiple targets and indications while working with cross functional teams and CROs -
Entrepreneur/ ParticipantEntrepreneurship Lab (Elabnyc) Bio & Health Tech Dec 2016 - Jun 2017New York, Ny, UsTechnology developed in post-doctoral work selected among the top in 20 NY/NJ by the ELabNYC accelerator program 2016-2017• Developed scientific, business, and IP strategies to launch a biotech startup based on the novel drug discovery platform technology developed in our lab (http://www.elabnyc.com/directory/arijit-bhowmick/) • Analyzed competing/related technologies and interacted with experts in the field to develop ideas for improving our platform • Identified niche areas for application based on SWOT analysis of our technology and unmet needs• Communicated our science to investors, lawyers, HCPs and industry professionals and built relationships for RnD and financing(Elab is a prestigious competitive Bio and Health Tech accelerator program in NYC run by Design Technologies and supported by Eli Lilly, Pfizer, Roche, Kaneka and Alexandria Launch labs. Every year Elab selects 20 promising innovations in biotech/health- tech to accelerate the development of technologies into successful businesses)-- -
Postdoctoral Scientist In Oligonucleotide Drug Discovery And Platform DevelopmentAlbert Einstein College Of Medicine Aug 2013 - Jun 2017Bronx, New York, UsLab of Matthew Levy • Developed a novel aptamer SELEX platform to discover fully chemically modified aptamers (Selected among the top 20 technologies from NY/NJ by the ELabNYC accelerator program 2016-2017)• Applied the platform to identify chemically modified aptamers to GPR75, PDL1 and fD (licensed from Einstein by a privately funded biotech)• Developed aptamer- siRNA/small molecule conjugates for targeted delivery• Worked on aptamer functionalized LNPs for delivery of mRNA and siRNA cargo• Spearheaded drug discovery efforts in an industry-academia collaboration from early discovery and screening for leads, lead optimization, characterization, and delivery to industry team• Key techniques : oligo solid phase synthesis and purification, siRNA and aptamer design, RNA folding and RNA-protein interaction, mRNA design and generation, SELEX, NGS, cell culture models for drug screening (2D/3D and primary cultures), binding assays (Octet, Biacore), Flowcytometry, cloning etc. -
Technology Transfer Intern; Office Of Biotechnology And Business DevelopmentAlbert Einstein College Of Medicine Jun 2014 - Jun 2016Bronx, New York, UsLicensing and commercialization of technologies developed at Einstein and Montefiore Medical Center (MMC)• Analyzed Invention Disclosures for patent-ability/marketability and performed scientific due diligence and competitive landscape analysis of technologies developed at Einstein and MMC.• Evaluated potential market opportunities for each technology. • Created tech summaries for each portfolio by translating complex scientific/clinical data into simple brief summary/presentation formats aimed at diverse audiences such as HCPs, investors, KOLs and industry leaders.• Executed marketing campaign for each portfolio by reaching out to and interacting with leading industry professionals.• Identified and contacted potential commercialization/licensing partners and participated in negotiation discussions resulting from marketing efforts.• Served as the primary liaison between Einstein researchers and interested external partners for the selected technologies.
Arijit Bhowmick, Ph.D. Skills
Arijit Bhowmick, Ph.D. Education Details
-
Albert Einstein College Of Medicine -
National Institute Of Immunology, New DelhiStructural Immunology
-
Dept. Of Chemistry, University Of PuneBiochemistry
-
Fergusson CollegeChemistry And Biotechnology
-
Dav Model Durgapur, IndiaHigh School
Frequently Asked Questions about Arijit Bhowmick, Ph.D.
What company does Arijit Bhowmick, Ph.D. work for?
Arijit Bhowmick, Ph.D. works for Insitro
What is Arijit Bhowmick, Ph.D.'s role at the current company?
Arijit Bhowmick, Ph.D.'s current role is Director | Head of Oligonucleotide Therapeutics drug discovery @Insitro.
What is Arijit Bhowmick, Ph.D.'s email address?
Arijit Bhowmick, Ph.D.'s email address is ar****@****ail.com
What schools did Arijit Bhowmick, Ph.D. attend?
Arijit Bhowmick, Ph.D. attended Albert Einstein College Of Medicine, National Institute Of Immunology, New Delhi, Dept. Of Chemistry, University Of Pune, Fergusson College, Dav Model Durgapur, India.
What are some of Arijit Bhowmick, Ph.D.'s interests?
Arijit Bhowmick, Ph.D. has interest in Pharma/biotech Due Diligence, Computational Biology, Medical Writing, Biotechnology Industry Consulting, Structure Based Drug Designing, Antibody Therapeutics, Drums, Transgenic Animals, Pharma Consulting, Music.
What skills is Arijit Bhowmick, Ph.D. known for?
Arijit Bhowmick, Ph.D. has skills like Protein Chemistry, Biochemistry, Flow Cytometry, Scientific Writing, Structural Biology, Monoclonal Antibodies, Antibodies, Molecular Cloning, Biotechnology, Transfection, Tissue Culture, Surface Plasmon Resonance.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial